Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenecteplase for Intravenous Stroke Thrombolysis in Recent DOAC Users
NCT07092709Phase 3Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Aug 2025
- Primary completion
- Sep 2028
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing Intravenous tenecteplase with Matched placebo (2 arms). Primary endpoint: Modified Rankin Scale score 0-1 at 90 days. Started Aug 2025; status: recruiting.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07092709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07092709.